In order to build on its existing leadership in epilepsy, UCB has agreed to acquire Neurona Therapeutics for US$650 M upfront and up to US$500 M in potential future milestone payments. Through the takeover, UCB picks up access to NRTX‑1001, a first‑in‑class neural cell therapy currently being evaluated for drug‑resistant mesial temporal lobe epilepsy. The transaction broadens UCB’s portfolio beyond traditional antiseizure medicines towards potentially disease modifying approaches, while highlighting its strategic interest in high-unmet need, treatment-refractory epilepsy segments and next-generation neurology assets.